Although elevated anti-CRC function was observed, considering the fact that CRC patients hold complicated mutational loads, such as diverse KRAS or BRAF mutations, our combination regimen still needs further confirmation in various CRC cells to be applied to clinical use. The gene discussed is BRAF; the disease is colorectal carcinoma.